Neuroleptic malignant syndrome--a cautionary tale and a surprising outcome.
Vigilance is required in order to detect the cardinal signs of neuroleptic malignant syndrome (NMS), especially after prolonged exposure to neuroleptics. In this case, NMS was diagnosed in a 29-year-old man, who had been on fluphenazine decanoate for over one year, coinciding with a cessation of his neuroleptic medication. Vigorous treatment, including assisted ventilation, was necessary, extending over three months. On recovery, his mental state and social functioning had undergone a sustained improvement sufficient for his release from hospital.
Cape
G
G
Mapperley Hospital, Nottingham.
D000203:Activities of Daily Living / Q000523:psychology; D000223:Adaptation, Psychological; D000328:Adult; D000987:Antisocial Personality Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003131:Combined Modality Therapy; D003422:Critical Care; D003620:Dantrolene / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D009460:Neurologic Examination / Q000187:drug effects; D012557:Schizoid Personality Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D012803:Sick Role; D012931:Social Environment; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis* / Q000188:drug therapy
D007980:Levodopa; D003620:Dantrolene; C011825:fluphenazine depot; D005476:Fluphenazine